Biogen Idec Inc. said its first-quarter profit jumped 12%, as strong sales of its pill-based multiple-sclerosis treatment Tecfidera drove revenue higher.
WSJ.com: US Business, Wall Street Journal: Business
Wed, 04/23/2014 - 4:33am
Biogen Idec Inc. said its first-quarter profit jumped 12%, as strong sales of its pill-based multiple-sclerosis treatment Tecfidera drove revenue higher.